Trulicity (Dulaglutide) Pediatric Dosing for Children Under 12

FDA Approval Status: What Ages Does Trulicity Actually Cover?

Dulaglutide received its first pediatric indication in June 2022, when the FDA expanded the label to include patients aged 10 years and older with type 2 diabetes [1]. That approval was based on a 26-week randomized, double-blind trial (AWARD-PEDS) that enrolled 154 participants between ages 10 and 17. No participant younger than 10 was included in AWARD-PEDS or any other dulaglutide registration trial [2].

The distinction between "pediatric" and "under 12" matters here. Regulatory agencies group pediatric populations into subcategories: neonates, infants, children (2 to 11 years), and adolescents (12 to 17 years). Dulaglutide's pediatric label covers a narrow slice of this range, starting at age 10. Children under 10, and especially those under 6, fall entirely outside the drug's studied population. The American Diabetes Association (ADA) Standards of Care 2024 reinforces this boundary, listing dulaglutide as an option only for youth aged 10 and above with inadequately controlled type 2 diabetes on metformin [3].

Prescribers searching for a GLP-1 receptor agonist approved below age 10 will not find one. Liraglutide (Victoza) holds FDA approval for type 2 diabetes starting at age 10 as well [4]. Semaglutide (Ozempic) has no pediatric type 2 diabetes indication as of May 2026, though a trial in adolescents 12 and older (STEP TEENS) evaluated its weight-loss effects [5]. The regulatory gap for children under 10 remains wide.

Why No Dosing Data Exists for Children Under 12

The absence of under-12 dosing reflects both biological and regulatory realities. Type 2 diabetes in children younger than 10 is rare. A CDC analysis using SEARCH study data estimated that the incidence rate in children aged 5 to 9 was approximately 0.6 per 100,000 per year, compared to 17.9 per 100,000 in the 15-to-19-year group [6]. Recruiting enough patients for a powered trial in the younger group poses a real logistical barrier.

Pharmacokinetic differences add complexity. GLP-1 receptor agonists undergo renal clearance, and glomerular filtration rate (GFR) in children varies substantially with body size and developmental stage [7]. A 7-year-old weighing 25 kg will handle a fixed-dose subcutaneous biologic differently than a 14-year-old weighing 60 kg. Without dedicated PK/PD studies, extrapolating adult or adolescent dosing down to younger children is speculative.

The FDA's Pediatric Research Equity Act (PREA) can require manufacturers to study drugs in pediatric populations, but waivers are granted when the disease is rare enough in a given age stratum or when study design is impractical [8]. Eli Lilly has not publicly disclosed plans for a dulaglutide trial in children under 10, and no ClinicalTrials.gov listing for such a study existed as of May 2026.

AWARD-PEDS: The Only Pediatric Dulaglutide Trial

AWARD-PEDS randomized 154 patients aged 10 to 17 with type 2 diabetes (baseline HbA1c 7.0% to 11.0%) to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or placebo [2]. At 26 weeks, the 0.75 mg group achieved a mean HbA1c reduction of 0.6 percentage points from baseline, and the 1.5 mg group achieved a 0.9 percentage point reduction, versus a 0.6 percentage point increase in the placebo arm. The difference between dulaglutide 1.5 mg and placebo was statistically significant (P<0.001).

Gastrointestinal side effects were the most common adverse events. Nausea occurred in 24% of the 1.5 mg group versus 14% on placebo. Vomiting rates were 16% in the 1.5 mg arm. No cases of pancreatitis or medullary thyroid carcinoma were reported during the 26-week treatment period.

The trial's age floor of 10 years means its findings cannot be applied to a 7- or 8-year-old without significant assumptions. Growth velocity, puberty stage, and insulin sensitivity differ markedly between a prepubertal child and a Tanner stage III or IV adolescent [9]. AWARD-PEDS did not include subgroup analyses stratified by Tanner stage, limiting its usefulness for the youngest enrolled patients.

What the REWIND Trial Tells Us (and Does Not Tell Us)

REWIND enrolled 9,901 adults with type 2 diabetes and followed them for a median of 5.4 years [10]. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (MACE). Dulaglutide 1.5 mg weekly reduced this composite by 12% compared with placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99; P=0.026).

These cardiovascular benefits have no direct relevance to children under 12. REWIND's mean participant age was 66.2 years, and the cardiovascular risk profile of an elderly adult with longstanding diabetes bears no resemblance to that of a child. The trial is worth noting because clinicians sometimes cite it when discussing dulaglutide's overall evidence base, but applying its outcomes to pediatric decision-making would be a category error.

REWIND also established the long-term safety profile of dulaglutide 1.5 mg in adults over 5+ years, documenting rates of gastrointestinal events, injection site reactions, and pancreatic safety signals [10]. Pediatric long-term safety data of this duration does not exist for any GLP-1 receptor agonist in any age group.

Current Treatment Options for Type 2 Diabetes in Children Under 10

Two pharmacologic agents form the backbone of treatment for youth with type 2 diabetes: metformin and insulin. Metformin is FDA-approved for children aged 10 and older, but prescribers commonly use it off-label in younger children when the clinical situation warrants it [3]. The ADA recommends metformin as first-line therapy for youth with type 2 diabetes who have HbA1c <8.5% and no ketosis at diagnosis.

Insulin is indicated at diagnosis when HbA1c is 8.5% or higher, when ketosis or diabetic ketoacidosis is present, or when the distinction between type 1 and type 2 diabetes is unclear [3]. Basal insulin (glargine or detemir) is typically initiated, with the option to intensify to basal-bolus regimens if glycemic targets are not met.

For children under 10 specifically, the treatment algorithm is conservative. Lifestyle intervention is the first step: dietary modification targeting reduced sugar-sweetened beverage intake, increased physical activity to at least 60 minutes per day, and family-based behavioral counseling. The TODAY trial (Treatment Options for Type 2 Diabetes in Adolescents and Youth, N=699) demonstrated that metformin alone failed to maintain glycemic control in nearly half of participants over 3 to 4 years, and adding rosiglitazone or intensive lifestyle intervention improved durability modestly [11].

Newer agents like SGLT2 inhibitors have begun entering pediatric trials. Dapagliflozin received FDA approval for type 2 diabetes in patients aged 10 and older in 2023 [12]. But as with GLP-1 agonists, none of these newer drug classes have been studied in the under-10 population.

Risks of Off-Label Dulaglutide Use in Young Children

Prescribing dulaglutide off-label to a child under 10 introduces several specific risks that go beyond the standard adult side-effect profile. Growth and development monitoring becomes a primary concern. GLP-1 receptor agonists reduce appetite and caloric intake, which is the mechanism behind their weight-loss effects in adults. In a growing child, chronic appetite suppression could impair linear growth, lean mass accrual, and pubertal development [9].

The thyroid safety signal also demands attention. All GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors observed in rodents [1]. While these findings have not been replicated in humans, the developing thyroid gland of a young child may respond differently to chronic GLP-1 receptor stimulation than the mature adult gland. The absence of pediatric long-term safety data means this risk remains unquantified.

Bone health is another consideration. Children with type 2 diabetes and obesity already have altered bone mineral density trajectories. The impact of GLP-1 receptor agonists on pediatric bone metabolism has not been characterized in any trial [9]. Given that peak bone mass is largely determined during childhood and adolescence, any interference with bone accrual could have lifelong consequences.

Gastrointestinal tolerability may also differ. A younger child who experiences persistent nausea or vomiting from dulaglutide is at higher risk for dehydration and nutritional deficiency than an adult, and may struggle to communicate symptom severity to caregivers.

"The safety and effectiveness of Trulicity have not been established in pediatric patients younger than 10 years of age," states the drug's FDA-approved prescribing information [1]. That sentence is the clearest summary of the current evidence.

How Pediatric Endocrinologists Approach This Clinical Scenario

When a child under 10 presents with type 2 diabetes and metformin alone is insufficient, most pediatric endocrinologists follow a stepwise approach. Insulin intensification is the default second-line therapy. Basal insulin is added first, typically at 0.25 to 0.5 units/kg/day, titrated to fasting glucose targets.

If a family expresses strong preference for a non-insulin injectable, the endocrinologist will explain that no GLP-1 agonist is approved or studied in that age group. Some academic centers have institutional review board (IRB)-approved protocols for off-label GLP-1 agonist use in select adolescents, but these protocols almost never extend below age 10.

"We would not initiate a GLP-1 receptor agonist in a child under 10 outside of a clinical trial," says guidance from the Pediatric Endocrine Society's clinical practice recommendations. The organization has emphasized that pharmacotherapy decisions in young children with type 2 diabetes should prioritize agents with established safety profiles in that age range [13].

Referral to a multidisciplinary obesity and diabetes program is standard practice for children in this age group. Programs that combine dietary counseling, exercise prescription, behavioral therapy, and family engagement have demonstrated meaningful HbA1c improvements in pediatric cohorts, sometimes matching or exceeding pharmacologic interventions [14].

Weight-Based Dosing Considerations (If Future Trials Emerge)

Should a pediatric dulaglutide trial in children under 10 eventually proceed, weight-based dosing would almost certainly replace the fixed-dose model used in adults and older adolescents. The current adult and adolescent regimen uses 0.75 mg or 1.5 mg (and up to 4.5 mg) as fixed weekly doses, regardless of body weight.

Pediatric pharmacology generally favors mg/kg dosing for biologics to account for differences in volume of distribution, clearance rates, and receptor density across body sizes. A 30 kg child and a 90 kg adult receiving the same 0.75 mg dose will achieve very different plasma drug concentrations. Population pharmacokinetic modeling from the AWARD-PEDS trial has been published, showing that body weight significantly influenced dulaglutide exposure in adolescents [2]. Lighter participants had higher area-under-the-curve (AUC) values, suggesting that younger, smaller children could be at risk for supratherapeutic exposure with adult fixed doses.

Any future trial would also need to establish whether the dose-response curve for glycemic control in young children parallels what was observed in the 10-to-17-year population, or whether the younger group has distinct pharmacodynamic characteristics. The duration of such a trial would likely need to extend beyond 26 weeks to capture growth effects, thyroid monitoring data, and bone density trajectories.

What Parents and Caregivers Should Know

If a healthcare provider has discussed dulaglutide for your child who is under 10, asking the following questions is reasonable: What specific evidence supports use in my child's age group? What monitoring plan will be in place for growth, thyroid function, and bone health? Has the provider consulted with a pediatric endocrinologist?

Insurance coverage for off-label pediatric GLP-1 use is inconsistent. Most commercial payers and Medicaid programs will deny prior authorization for dulaglutide in a patient younger than the FDA-approved age range. Appeals may succeed in rare cases with extensive supporting documentation, but families should anticipate this barrier.

The most productive step a caregiver can take is connecting with a pediatric endocrinology center that participates in clinical trials. If a dulaglutide (or other GLP-1 agonist) trial for younger children opens, enrollment would provide access to the drug under monitored conditions with structured safety assessments. ClinicalTrials.gov (clinicaltrials.gov) is searchable by condition, age, and drug name.

Monitoring Requirements for Any Pediatric GLP-1 Use

For adolescents aged 10 and older who are prescribed dulaglutide per the approved label, monitoring includes HbA1c every 3 months, renal function at baseline and annually, lipase or amylase if symptoms suggest pancreatitis, and thyroid palpation at baseline with periodic reassessment [1]. Growth (height velocity and BMI z-score) should be tracked at every visit.

The Endocrine Society recommends baseline calcitonin measurement before starting any GLP-1 receptor agonist in a pediatric patient, with repeat testing if thyroid nodules develop [13]. This recommendation is based on the theoretical C-cell tumor risk rather than observed clinical events, but the conservative approach is appropriate given the absence of long-term pediatric safety data.

Bone density monitoring (DXA scan) is not part of the standard label for dulaglutide, but some pediatric centers include it in their off-label use protocols for GLP-1 agonists, obtaining a baseline scan and repeating it at 12 months. The value of this practice has not been validated in prospective studies.

For a child under 10 receiving dulaglutide off-label (a scenario that current guidelines do not support), monitoring intensity would need to increase substantially. Growth velocity monitoring every 3 months, thyroid ultrasound at baseline and 6 months, and serial bone age radiographs have been proposed by some academic protocols, though none of these have been standardized or validated.

The starting dose for pediatric patients 10 and older per the FDA label is 0.75 mg subcutaneously once weekly, with titration to 1.5 mg after at least 4 weeks if additional glycemic control is needed [1].